TNFSF11 and ovarian carcinoma: Based on the recent landmark studies by the Penninger & Lindeman groups [1, 2], clinical trials are warranted to test the efficacy of the anti-RANKL antibody denosumab to prevent breast/ovarian tumorigenesis in carriers of BRCA1/2 mutations, and likely in women with non-BRCA1/2 mutations at very high risk of developing breast/ovarian cancer.